uniQure N.V. (QURE) Stock Profile & Financial OverviewuniQure N.V.
QURE Company Overview & Business Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Key Information
Current Trend for QURE
An assessment of the current trend environment for QURE, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for QURE is a Sideways Consolidation (Range-Bound Environment).
The weekly trend is in a consolidation regime, which automatically downgrades the daily signal to sideways conditions. This environment favors short-term mean-reversion rather than trend-following.
- The weekly context is non-trending (sideways), which typically caps the duration and magnitude of daily trend moves.
- Price is currently trending at a healthy distance, sitting 1.01 ATR away from the adaptive KAMA baseline.
- The current market structure is holding within recent defined ranges.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, QURE in a strong expansion phase; Long-term trend is bullish.
Trend Strength: QURE last closed at 25.19, trading 1.2 ATR above the adaptive KAMA baseline (22.43). Technical Classification: Confirmed High-Momentum Uptrend.
Trend Score: Technical Score: 95/100. Classification: Strong/Established. Alignment: High. Logic: Full multi-timeframe alignment with strong momentum filters.
SuperTrend Risk: Risk indicators: No active structural constraints identified.
Risk Skew: Multi-timeframe risk skew is currently assessed as Conflicted / Pullback. The daily decline is occurring within a larger weekly uptrend. This suggests a corrective phase, where downside risk meets significant long-term structural support.
Key Levels: Key technical references: Spot 25.19, KAMA 22.43.